Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
11018312 | American Journal of Obstetrics and Gynecology | 2018 | 9 Pages |
Abstract
While the performance of the fourth-generation ARCHITECT HIV Ag/Ab Combo assay among pregnant women is comparable with that reported in nonpregnant populations, clinical implications of using a screening test with a positive predictive value of 83% in pregnancy are significant. When the qualitative RNA assay result is unavailable, absence of risk factors in combination with an ARCHITECT HIV Ag/Ab assay S/Co ratio <5 and nonreactive differentiation assay provide sufficient evidence to support deferral of unnecessary intrapartum interventions while awaiting qualitative RNA results.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Emily H. MD, Devin MD, Donna MT(ASCP)SM, Sarah MD, Vanessa L. MD, Donald D. PhD, Scott W. MD,